First patients enrolled in Phase I trial with KQB548, an investigational KRAS inhibitor designed to treat KRAS G12D-mutated tumors
Facility marks cornerstone of $50 billion investment in medicines R&D and manufacturing in America
The new line features advanced isolator technology to deliver enhanced sterility assurance, throughput and operational precision
Lilly's Omvoh is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis
RedHill will receive $500,000 in guaranteed payments, including a $250,000 upfront payment and $250,000 in fixed payments due within 18 months
Positive volume growth was observed in key therapies such as respiratory (13.2% yoy), anti-neoplastics (12.1% yoy) and cardiac (4.8% yoy) during September 2025
Stephan brings more than 20 years of leadership experience in the pharmaceutical industry
Medico Remedies receives order worth US$ 1,781,000
Max and Luna personify HRV Pharma’s core values of trust, loyalty, and authentic partnership
Subscribe To Our Newsletter & Stay Updated
